期刊文献+

奥曲肽对胰腺癌细胞增殖、凋亡和血管内皮生长因子表达的影响 被引量:4

The effects of Octreotide on proliferation、apoptosis and VEGF expression in human pancreatic cancer cell line
下载PDF
导出
摘要 目的:探讨生长抑素类似物奥曲肽对胰腺癌细胞增殖、凋亡和血管内皮生长因子(VEGF)表达的影响。方法:分别加入不同浓度奥曲肽培养细胞24 h,采用四甲基偶氮唑蓝(MTT)法检测细胞增殖,原位末端转移酶标记法(TUNEL)检测细胞凋亡,实时荧光定量PCR(RT-PCR)法检测细胞VEGF mRNA表达。结果:随着奥曲肽浓度的升高,细胞增殖受到抑制,凋亡率升高,VEGFmNRA表达下降,与对照组比有显著性差异(P<0.05)。结论:奥曲肽可抑制胰腺癌细胞增殖、促进胰腺癌细胞凋亡和降低胰腺癌细胞VEGF的表达。 Objective: To study the effects of somatostatin analogue Octreotide on proliferation、apoptosis and VEGF expression in human pancreatic cancer cell line.Methods: Proliferation was measured by MTT assay.Apoptosis was detected by TUNEL method.The expression of VEGF was analyzed by RT-PCR.Results: Octreotide inhibited the growth and VEGF expression of SW1990,and promoted the apoptosis in a dose-dependent manner(P0.05).Conclusion: Octreotide may be used to clinical treatment by promoting apoptosis、inhibiting proliferation and VEGF expression in pancreatic cancer patient.
出处 《肠外与肠内营养》 CAS 北大核心 2012年第2期99-101,106,共4页 Parenteral & Enteral Nutrition
关键词 奥曲肽 胰腺癌 增殖 凋亡 血管内皮生长因子 Octreotide Pancreatic cancer Proliferation Apoptosis Vascular endothelial growth factor
  • 相关文献

参考文献5

二级参考文献35

共引文献55

同被引文献58

  • 1张月枚.医护一体化在小剂量肝素联合奥曲肽对原发性肝癌TACE术后肝外转移患者中的护理干预效果[J].世界最新医学信息文摘,2020(61):168-169. 被引量:1
  • 2陈仲庚.艾森克人格问卷的项目分析[J].心理学报,1983,15(2):211-218. 被引量:381
  • 3Saif MW. Advancements in the management of pancreatic cancer [ J]. J Pancreas,2013,14(2) :112 -118.
  • 4Stomiolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine:resuhs for o- ver 3000 patients with panereatic carcinoma [ J]. Cancer, 1999,85 (6) :1261 - 1268.
  • 5Ioka T, Katayama K, Tanaka S, et al. Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post - marketing surveillance in Japan [J]. Jpn J Clin 0ncol,2013,43(2) :139 - 145.
  • 6Giuliani F, Di Maio M, Colucei G, et al. Conventional chemotherapy of advanced pancreatic cancer [ J]. Curr Drug Targets,2012, 13 (6) :795 -801.
  • 7Colucci G, Labianca R, Di Costanzo F. Randomized phase III trial of gemcitabine plus cisplatin compared with single - agent gemcit- abine as first - line treatment of patients with advanced pancreatic cancer:the GIP-1 study[J]. J Clin Oncol,2010,28(10) :1645 - 1651.
  • 8Ciliberto D, Botta C, Correale P, et al. Role of gemcitabine - based combination therapy in the management of advanced pancreatic cancer: a meta - analysis of randomised trials [ J ]. Eur J Cancer, 2013,49(3) :593 -603.
  • 9Hidalgo M. Pancreatic cancer [ J ]. N Engl J Med,2010,362 ( 17 ) : 1605 - 1617.
  • 10Chan MM, Mengshol JA. Octreotide:a drug often used in the criti- cal care setting but not well understood [ J ]. Chest,2013,144 (6) : 1937 - 1945.

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部